Form 4: United Therapeutics Director Christopher Causey Acquires Restricted Stock Units

Director Christopher Causey received 1,190 restricted stock units of United Therapeutics Corporation on July 25, 2024, which vest on the one-year anniversary of the grant date.

Summary

• On July 25, 2024, Christopher Causey, a director of United Therapeutics Corporation, was granted 1,190 restricted stock units (RSUs).
• These RSUs represent the right to receive one share of United Therapeutics Corporation common stock per unit upon vesting.
• The RSUs were awarded as part of the annual non-employee director compensation.
• The RSUs vest on July 25, 2025, which is the one-year anniversary of the grant date.
• Following the transaction, Mr. Causey directly owns 1,190 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (granting of restricted stock units to a director), which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders, incentivizing long-term value creation.

Industry Context

The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to attract and retain board members and align their interests with those of shareholders. This is a standard compensation practice for non-employee directors.

Comparison to Industry Standards

• Director compensation packages, including stock options and restricted stock units, are common across the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation for their non-employee directors to align their interests with shareholders.

Stakeholder Impact

• The granting of RSUs to a director can have a slightly positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates